Cetuximab or cisplatin as a radiosensitizer in locoregionally advanced head and neck cancer: recent results

Recently, Magrini et al. reported the results of a small randomized phase II study that included 70 patients with locoregionally advanced head and neck cancer who were randomly assigned to treatment with weekly cisplatin and radiotherapy (RT) or cetuximab and RT (1).